Myomo (NYSEAMERICAN:MYO) Director Thomas Kirk Buys 31,605 Shares

Myomo, Inc. (NYSEAMERICAN:MYO) Director Thomas Kirk purchased 31,605 shares of the business’s stock in a transaction on Friday, May 15th. The stock was bought at an average cost of $0.91 per share, with a total value of $28,760.55. Following the purchase, the director owned 585,462 shares in the company, valued at approximately $532,770.42. This represents a 5.71% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this link.

Myomo Price Performance

MYO stock opened at $0.84 on Tuesday. The company has a debt-to-equity ratio of 1.21, a current ratio of 2.73 and a quick ratio of 2.36. Myomo, Inc. has a one year low of $0.61 and a one year high of $3.45. The stock has a market cap of $32.42 million, a PE ratio of -2.33 and a beta of 1.39. The firm has a 50 day simple moving average of $0.76 and a two-hundred day simple moving average of $0.84.

Institutional Investors Weigh In On Myomo

A number of institutional investors have recently made changes to their positions in MYO. Cubist Systematic Strategies LLC boosted its stake in shares of Myomo by 157.4% in the 1st quarter. Cubist Systematic Strategies LLC now owns 49,101 shares of the company’s stock valued at $236,000 after purchasing an additional 30,028 shares in the last quarter. Dynamic Technology Lab Private Ltd purchased a new stake in shares of Myomo in the 1st quarter valued at $75,000. Jane Street Group LLC boosted its stake in shares of Myomo by 84.2% in the 1st quarter. Jane Street Group LLC now owns 162,658 shares of the company’s stock valued at $782,000 after purchasing an additional 74,338 shares in the last quarter. Acadian Asset Management LLC purchased a new stake in shares of Myomo in the 1st quarter valued at $114,000. Finally, Geode Capital Management LLC boosted its stake in shares of Myomo by 160.8% in the 2nd quarter. Geode Capital Management LLC now owns 669,281 shares of the company’s stock valued at $1,446,000 after purchasing an additional 412,631 shares in the last quarter. Hedge funds and other institutional investors own 44.99% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Craig Hallum reaffirmed a “buy” rating on shares of Myomo in a research note on Tuesday, March 10th. Four equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $7.67.

Myomo Company Profile

Myomo, Inc (NYSE American: MYO) is a medical robotics company specializing in developing and commercializing powered orthotic devices designed to restore mobility and function for individuals with upper-limb weakness. The company’s flagship product, the MyoPro®, is an FDA-cleared, wearable robotic orthosis that leverages proprietary sensors and actuators to detect and amplify users’ own muscle signals, enabling patients with conditions such as stroke, spinal cord injury, muscular dystrophy and other neuromuscular disorders to perform daily activities with greater independence.

Myomo markets the MyoPro through a network of licensed orthotic and prosthetic professionals, clinics and hospitals across North America.